4D Molecular Therapeutics (NASDAQ:FDMT Get Rating) is one of 264 public companies in the Biological products, except diagnostic industry, but how does it weigh in compared to its peers? We will compare 4D Molecular Therapeutics to similar companies based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

This table compares 4D Molecular Therapeutics and its peers net margins, return on equity and return on assets.

76.6% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of shares of all Biological products, except diagnostic companies are owned by institutional investors. 11.2% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 16.4% of shares of all Biological products, except diagnostic companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

4D Molecular Therapeutics peers have higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

This is a summary of current ratings and price targets for 4D Molecular Therapeutics and its peers, as provided by MarketBeat.

4D Molecular Therapeutics presently has a consensus target price of $26.00, suggesting a potential upside of 157.94%. As a group, Biological products, except diagnostic companies have a potential upside of 92.79%. Given 4D Molecular Therapeutics stronger consensus rating and higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than its peers.

4D Molecular Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics peers have a beta of 0.75, meaning that their average stock price is 25% less volatile than the S&P 500.

4D Molecular Therapeutics beats its peers on 8 of the 13 factors compared.

(Get Rating)

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Link:
Comparing 4D Molecular Therapeutics (FDMT) and Its Rivals - Defense World

Comments are closed.